Karyopharm Therapeutics Q4 2023 GAAP EPS $(0.36) Misses $(0.30) Estimate, Sales $33.75M Miss $35.40M Estimate
Portfolio Pulse from Benzinga Newsdesk
Karyopharm Therapeutics reported Q4 2023 earnings with a GAAP EPS of $(0.36), missing the $(0.30) estimate, and sales of $33.75M, missing the $35.40M estimate. This represents a slight 0.50% increase in sales compared to the same period last year.
February 29, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Karyopharm Therapeutics missed Q4 2023 earnings and sales estimates, with a slight year-over-year sales increase.
Missing both earnings and sales estimates typically leads to negative investor sentiment in the short term. The slight increase in year-over-year sales may not be sufficient to offset the negative impact of missing estimates.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100